IP Library Granted Patent US 8,449,928
Granted Patent B2
US 8,449,928 · App. 13/539,531 · Granted May 28, 2013

Cleanser compositions and methods for using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,449,928
App. No.
13/539,531
Granted
May 28, 2013
Kind
B2
Abstract

The present invention is directed to anti-microbial cleanser compositions comprising linalool, hinokitiol and dipropylene glycol. The present invention further provides methods for using these compositions to maintain eyelid hygiene, to treat an ocular disorder or to clean a skin surface. The cleanser compositions of the present invention can be in the form of a foam, gel or liquid.

Claims (77)

1. A method of cleansing the eyelid or the skin surrounding the eyelid of a subject consisting essentially of applying to the eyelid or the skin surrounding the eyelid of the subject a cleanser composition consisting essentially of 0.5-2% by weight linalool in the total composition, 0.01-5% by weight hinokitiol in the total composition and 1-50% by weight in the total composition of a compound selected from the group consisting of propylene glycol, ethylene glycol and dipropylene glycol in the total composition.

2. The method of claim 1 , wherein the cleanser composition is applied as a foam, gel or liquid.

3. The method of claim 1 wherein the body surface is cleaned to treat an ocular disorder.

4. The method of claim 3 , wherein the ocular disorder is selected from the group consisting of dry eye, excessive bacteria on the eyelid dermis, Meibomian gland dysfunction, blepharitis, acne rosacea, scalp dandruff, seborrheic dermatitis, chalazion, hordeolum, sty infectious conjunctivitis, corneal ulcer, demodex infestation, and any combination thereof.

5. The method of claim 4 , wherein the ocular disorder is anterior or posterior blepharatis.

6. The method of claim 1 , wherein the composition is effective against at least one of the following microorganisms: Staphylococcus aureus, Pseudomonas aeruginosa, Branhamella catarrhalis, Escherichia coli, Serratia marcescens, Staphylococcus epidermidis , and Pityrosporum ovale.

7. The method of claim 6 , wherein the Staphylococcus aureus is methicillin resistant Staphylococcus aureus.

8. A method of cleansing the eyelid or the skin surrounding the eyelid of a subject consisting essentially of applying to the eyelid or the skin surrounding the eyelid of the subject an aqueous cleanser composition consisting essentially of the following components in approximately the following concentrations as a percent by weight in the total composition:

(a) a blend of PEG-80, sorbitan laurate,

 0.5-10.0%;

sodium trideceth sulfate, cocamidopropyl

betaine, sodium lauroamphoacetate,

PEG-150 distearate, and sodium

laureth-13 carboxylate

(b) Decyl Glucoside

 0.2-10.0%;

(c) Linalool

 0.5-2.0%;

(d) Cocamidopropyl PG-Dimonium

0.01-5.0%;

Chloride Phosphate

(e) Trisodium EDTA

0.01-1.0%;

(f) Allantoin

0.01-1.0%;

(g) Panthenol

0.01-1.0%;

(h) Hinokitiol

0.01-5.0%;

(i) Tea Tree Oil

0.005-2.0%; 

(j) Vitamin E Acetate

0.005-2.0%; 

(k) Water

  0.0-98.15%;

(l) Dipropylene glycol

    1.0-50.0%; and

(m) Cocamidopropyl betaine

   0.1-20.0%.

9. A method of cleansing the eyelid or the skin surrounding the eyelid of a subject consisting essentially of applying to the eyelid or the skin surrounding the eyelid of the subject an aqueous cleanser composition consisting essentially of the following components in approximately the following amounts as a percent by weight in the total composition:

(a) a blend of PEG-80, sorbitan laurate, sodium trideceth sulfate, cocamidopropyl betaine, sodium lauroamphoacetate, PEG-150 distearate, and sodium laureth-13 carboxylate 3.8%;

(b) Decyl Glucoside

1.7%   

(c) Linalool

0.9%;  

(d) Cocamidopropyl PG-

0.2%;  

Dimonium Chloride Phosphate

(e) Trisodium EDTA

0.1%;  

(f) Allantoin

0.1%;  

(g) Panthenol

0.1%   

(h) Hinokitiol

0.05%; 

(i) Tea Tree Oil

0.025%; 

(j) Vitamin E Acetate

0.01%; 

(k) Water

68.215%; 

(l) Dipropylene glycol

23.0%; and 

(m) Cocamidopropyl betaine

2.0%.

10. The method of claim 1 , wherein the pH range of the cleanser composition is about 4.5-6.0.

11. The method of claim 1 , wherein the pH range of the cleanser composition is about 5.3-5.7.

12. A method of cleansing the eyelid or the skin surrounding the eyelid of a subject consisting essentially of applying to the eyelid or the skin surrounding the eyelid of the subject an aqueous cleanser composition consisting essentially of 0.5-2% by weight linalool in the total composition, 0.01-5% by weight hinokitiol in the total composition, 1-50% by weight in the total composition of a compound selected from the group consisting of propylene glycol, ethylene glycol and dipropylene glycol in the total composition, and cocamidopropyl PG-dimonium chloride phosphate.

13. The method of claim 1 , wherein the composition is in the form of a foam.

14. The method of claim 1 , wherein the cleanser composition is formulated such that upon application to the body surface of the subject the cleanser composition does not substantially damage or irritate the body surface.

15. A method of cleansing the eyelid or the skin surrounding the eyelid of a subject consisting essentially of applying to the eyelid or the skin surrounding the eyelid of the subject an aqueous cleanser composition consisting essentially of 0.5-2% linalool in the total composition, 0.01-5% by weight hinokitiol in the total composition, 1-50% by weight in the total composition of a compound selected from the group consisting of propylene glycol, ethylene glycol and dipropylene glycol in the total composition, and between about 0.1% and about 20% by weight cocamidopropyl betaine in the total composition.

16. The method of claim 15 wherein the concentration of cocamidopropyl betaine is between about 0.5% and about 10% by weight in the total composition.

17. The method of claim 15 wherein the concentration of cocamidopropyl betaine is about 2% by weight in the total composition.

18. The method of claim 15 wherein the cleanser composition is applied as a foam.

19. The method of claim 15 wherein the pH range of the cleanser composition is about 4.5-6.0.

20. The method of claim 15 wherein the pH range of the cleanser composition is about 5.3-5.7.

Assignments (21)
SECURITY INTEREST Recorded Jul 24, 2026
From: MEDTECH PRODUCTS INC.; INSIGHT PHARMACEUTICALS CORPORATION; DENTEK ORAL CARE, INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075392/0725 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS @ REELS AND FRAMES: 053954/0755 AND 053955/0060 Recorded Jul 7, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS ADMINISTRATIVE AGENT
To: AKORN OPERATING COMPANY LLC
Reel/Frame 064234/0872 →
CORRECTION BY DECLARATION TO CORRECT THE 10 ERRONEOUSLY NULLIFIED PROPERTIES ON COVER SHEET AT REEL 057970 FRAME 0475. ASSIGNOR HEREBY CONFIRMS THAT THE 10 PROPERTIES LISTED THERE AND HEREIN SHOULD NOT HAVE BEEN NULLIFIED. Recorded Nov 12, 2021
From: AKORN OPERATING COMPANY LLC
To: MEDTECH PRODUCTS INC.
Reel/Frame 058104/0741 →
CORRECTION BY NULLIFICATION TO CORRECT INCORRECTLY RECORDED PROPERTY NUMBERS AT REEL/FRAME 57222/0489. ASSIGNOR HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 25, 2021
From: AKORN OPERATING COMPANY LLC
To: MEDTECH PRODUCTS INC.
Reel/Frame 057970/0475 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2021
From: AKORN OPERATING COMPANY LLC
To: MEDTECH PRODUCTS INC.
Reel/Frame 057222/0489 →
RELEASE OF SECURITY INTEREST Recorded Jul 8, 2021
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: AKORN, INC.; AKORN INTERMEDIATE COMPANY LLC; AKORN OPERATING COMPANY, LLC
Reel/Frame 056794/0730 →
RELEASE OF SECURITY INTEREST Recorded Jul 8, 2021
From: MIDCAP FUNDING IV TRUST
To: AKORN OPERATING COMPANY, LLC
Reel/Frame 056794/0811 →
RELEASE OF SECURITY INTEREST RECORDED AT 032714/0440 Recorded May 10, 2021
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: ADVANCED VISION RESEARCH, INC.
Reel/Frame 056194/0806 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 052753/0356 Recorded May 3, 2021
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: ADVANCED VISION RESEARCH, INC.
Reel/Frame 056122/0720 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 032714/0411 Recorded Mar 29, 2021
From: JPMORGAN CHASE BANK, N.A.
To: ADVANCED VISION RESEARCH, INC.
Reel/Frame 055759/0646 →
ENTITY CONVERSION Recorded Feb 8, 2021
From: ADVANCED VISION RESEARCH, INC.
To: ADVANCED VISION RESEARCH, LLC
Reel/Frame 055257/0224 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SCHEDULE OF PATENT APPLICATIONS AND GRANTED PATENTS TO BE ASSIGNED TO AKORN OPERATING COMPANY LLC PREVIOUSLY RECORDED ON REEL 054202 FRAME 0382. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 1, 2020
From: AKORN, INC.; ADVANCED VISION RESEARCH, LLC; HI-TECH PHARMACAL CO., LLC
To: AKORN OPERATING COMPANY, LLC
Reel/Frame 055326/0694 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Nov 5, 2020
From: AKORN OPERATING COMPANY LLC
To: MIDCAP FUNDING IV TRUST
Reel/Frame 054333/0247 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2020
From: AKORN, INC.; ADVANCED VISION RESEARCH, LLC; HI-TECH PHARMACAL CO., LLC
To: AKORN OPERATING COMPANY, LLC
Reel/Frame 054202/0382 →
SECURITY INTEREST Recorded Oct 1, 2020
From: AKORN OPERATING COMPANY LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 053954/0755 →
SECURITY INTEREST Recorded Oct 1, 2020
From: AKORN OPERATING COMPANY LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 053955/0060 →
SECURITY INTEREST Recorded May 26, 2020
From: ADVANCED VISION RESEARCH, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 052753/0356 →
SECURITY INTEREST Recorded Apr 1, 2020
From: JPMORGAN CHASE BANK, N.A., AS RESIGNING ADMINISTRATIVE AGENT
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SUCCESSOR ADMINISTRATIVE AGENT
Reel/Frame 052284/0618 →
SECURITY INTEREST (ABL) Recorded Apr 18, 2014
From: ADVANCED VISION RESEARCH, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 032714/0411 →
SECURITY INTEREST (TERM LOAN) Recorded Apr 18, 2014
From: ADVANCED VISION RESEARCH, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 032714/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2013
From: GILBARD, JEFFREY P.; DOUYON, YANICK; HUSON, ROBERT B.
To: ADVANCED VISION RESEARCH, INC.
Reel/Frame 030294/0077 →